Clinical Trial Update: Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating CD8-enriched tumor-infiltrating lymphocytes for metastatic melanoma. The study was terminated and results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• CD8-enriched tumor-infiltrating lymphocytes

Snippet

Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: Skin Cancer, Metastatic Melanoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2015-10-26